...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.
【24h】

Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

机译：与紫杉醇化疗结合异环磷酰胺作为三线疗法的病人与小细胞肺癌预处理。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The efficacy of salvage regimens for small cell lung cancer remains to be established. We evaluated the efficacy and safety of the paclitaxel and ifosfamide (PI) combination chemotherapy salvage regimen in heavily pretreated small cell lung cancer (SCLC) patients. Thirty-five patients who had received more than two prior chemotherapy regimens were treated with PI chemotherapy. Paclitaxel (175 mg/m(2)) was administered on day 1 and ifosfamide (2500 mg/m(2)) on day 1-2 every 3 weeks. Thirty-three patients were available for treatment response evaluation. Median age was 63 years (range, 40-78) and Eastern Cooperative Oncology Group (ECOG) performance scores of 0/1/2 were 29.4%, 61.8%, and 11.8%, respectively. A median of 2 cycles (range, 1-6) of chemotherapy were administered. The overall response rate (RR) in the intent-to-treat population was 20.0% (95% Confidence Interval (CI), 6.7-33.3%) with 7 partial responses (PR) and no complete response (CR). Patients who responded to previous chemotherapy just before PI showed significantly higher RR than non-responders (RR, 57.1% versus 10.7%, P=.023). After a median follow-up of 8.8 months (range, 1.6-14.7), the median time to progression was 3.3 months (95% CI, 2.3-4.4) and the median overall survival was 7.6 months (95% CI, 6.7-8.5). The most common toxicity observed was mild nausea/vomiting and grade 3/4 adverse events were observed in 4 (11.4%) patients. There were no treatment-related deaths in the study. Our findings suggest that salvage PI chemotherapy is a feasible and well tolerated regimen for previously treated SCLC patients. Further studies are warranted to define the effects of PI chemotherapy on quality of life and survival benefits.
机译：小细胞的救助方案的疗效肺癌还有待建立。评估的有效性和安全性紫杉醇和异环磷酰胺(PI)的组合在严重化疗救助方案小细胞肺癌(SCLC)预处理病人。前两个以上化疗方案对待π化疗。毫克/米(2))是在第一天和异环磷酰胺(2500毫克/米(2)每3周1 - 2天。33例患者可用治疗反应评估。年(范围、40 - 78)和东部合作许多0/1/2肿瘤组(ECOG)性能分别是29.4%、61.8%和11.8%。中位数2周期化疗(范围1 - 6)接种。intent-to-treat人群(95% 20.0%可信区间(CI), 6.7 -33.3%) 7局部反应(PR),没有完整的响应(CR)。化疗前π显示显著RR高于无(RR, 57.1%10.7%, P = 0)。个月(范围1.6 - -14.7),平均时间发展是3.3个月(95% CI, 2.3 - -4.4)中位总生存期是7.6个月(95%CI, 6.7 - -8.5)。轻度恶心/呕吐和3/4级不良事件在4例(11.4%)病人中被观察到。没有治疗相关的死亡。我们的研究表明,打捞π化疗容忍的方案是可行的,好吗以前SCLC患者治疗。保证定义π的影响吗化疗对生活质量和生存的好处。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号